169 related articles for article (PubMed ID: 6779210)
1. Immunological reactivity in the lymph nodes of the host following experimental cancer immunotherapy utilizing polymerized autologous tumor tissue particles.
Syrjänen KJ; Soimakallio S
Neoplasma; 1980; 27(4):387-98. PubMed ID: 6779210
[TBL] [Abstract][Full Text] [Related]
2. Polymerised autologous tumor tissue particles in experimental cancer immunotherapy with special reference to the effects on the immune system of the host.
Syrjänen KJ; Soimakallio S
Arch Geschwulstforsch; 1980; 50(8):724-34. PubMed ID: 6784699
[TBL] [Abstract][Full Text] [Related]
3. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. IV. Lymph node immunoreactivity and cell-mediated cytotoxicity.
Laatikainen A; Syrjänen K; Mäntyjärvi R; Tosi P
Neoplasma; 1987; 34(4):431-9. PubMed ID: 3116439
[TBL] [Abstract][Full Text] [Related]
4. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. III. Morphometric assessment of the dynamic changes in post-capillary venules as regulatory elements of lymphocyte recirculation in tumor-draining lymph nodes.
Tosi P; Syrjänen K; Cintorino M; Mäntyjärvi R; Luzi P; Miracco C; Laatikainen A; Leoncini L; Santopietro R
Arch Geschwulstforsch; 1987; 57(1):7-15. PubMed ID: 3105513
[TBL] [Abstract][Full Text] [Related]
5. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
Germain RN; Williams RM; Benacerraf B
Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
[TBL] [Abstract][Full Text] [Related]
6. Experimental cancer immunotherapy in DBA/2 mouse-mastocytoma model utilizing autologous tumor tissue polymerised with ethylchlorformiate.
Soimakallio S; Syrjänen KJ
Exp Pathol (Jena); 1980; 18(6):346-52. PubMed ID: 6774879
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
9. EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells.
Müller M; Gounari F; Prifti S; Hacker HJ; Schirrmacher V; Khazaie K
Cancer Res; 1998 Dec; 58(23):5439-46. PubMed ID: 9850077
[TBL] [Abstract][Full Text] [Related]
10. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression in a murine B cell leukemia (BCL1): role of an adherent cell in the suppression of primary in vitro antibody responses.
Anderson SA; Isakson PC; Puré E; Muirhead M; Uhr JW; Vitetta ES
J Immunol; 1981 Apr; 126(4):1603-7. PubMed ID: 6451649
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
15. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
[TBL] [Abstract][Full Text] [Related]
16. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
17. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
[TBL] [Abstract][Full Text] [Related]
18. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
